TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05485064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: The investigator 1 use fentanyl to sedate patients coordinate with remimazolam

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: eletroacupuncture(transcutaneous electrical acupuncture point stimulation )
Description: The investigator 1 use electroacupunture(transcutaneous electrical acupuncture point stimulation )to coordinate with remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo needle
Description: The investigator 1 use placebo needle to sedate patients coordinate with remimazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam
Description: The investigator 1 use remimazolam to sedate patients coordinate with eletroacupuncture(transcutaneous electrical acupuncture point stimulation )or placebo needle
Study: NCT04736303

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS
Description: The implementation of BIS monitoring
Study: NCT05168163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Given PO
Study: NCT05591105

Intervention type: DRUG
Intervention: Control Group
Description: At the end of surgery, they will continue receiving analgesia according the schedule and, addicionally, lidocaine (1 mg/kg/h) and Ketamine (0,15 mg/kg/h) for 90 minute as part of postoperative analgesia.

Intervention type: DRUG
Intervention: Placebo
Description: At the end of surgery, they will continue receiving analgesia according the schedule.
Study: NCT04870333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niclosamide
Description: 140μL of a 1% niclosamide ethanolamine solution in each nostril twice daily, equivalent to 1.4mg of niclosamide ethanolamine salt per nostril twice daily, approximately 12 hours apart. Total daily dose 5.6mg niclosamide ethanolamine salt (4.7mg free niclosamide acid). Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140μL of a matching placebo solution in each nostril twice daily. Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Participants will be prescribed ciclesonide once daily, administered as follows:~Two puffs (320 μg) inhaled via mouth sequentially One puff (160 μg) inhaled via nose Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo: two puffs inhaled via mouth sequentially and one puff inhaled via nose.~Treatment duration will be 6-9 months or up to 28 days after COVID-19 diagnosis unless hospitalised. Participants hospitalised with a diagnosis of COVID-19 should stop the randomised treatment immediately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotrovimab
Description: There will be a single infusion of sotrovimab administered at the beginning of the study.~500mg of sotrovimab solution (8mL) will be diluted in 42mL of 0.9% sodium chloride and administered by intravenous infusion. 50mLs to be infused over 30 minutes with a 0.2 micrometre inline filter. Four vials will be required for a 2000 mg dose.
Study: NCT04870333

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There will be a single infusion placebo, in the form of 100mL 0.9% sodium chloride, administered at the beginning of the study.
Study: NCT06360341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emergency Department Digital Pain Self-Management Intervention (EDPSI)
Description: The EDPSI is a developed supplemental digital video for patients presenting to the emergency department with acute low back pain (aLBP). The content consists of self-management approaches for diverse adult patient preferences including biopsychosocial contributors to pain and clinical practice guidelines to self-management options. Highlights of the discharge instructions summary include follow-up with provider, red flag warnings, and medication safety. Actor demonstration of ergonomics and range of motion movements provide application of Physical Therapy (PT)-based preventative strategies. Combination therapies including PT counseling, complementary alternative medicine (acupuncture, massage, yoga, or Pilates), and use of and safety with ice or heat thermal therapies. Active participation, stress management, and involvement of support systems are addressed.
Study: NCT04922957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLOCETRA-OTS
Description: The product contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension containing early apoptotic cells.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ringer's lactate solution
Study: NCT06462027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cells (1 unit)
Description: 500 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Packed Red Blood Cells (2 units)
Description: 1000 mL of packed red blood cells administered intravenously 10-20 minutes after CA onset, provided Return of Spontaneous Circulation (ROSC) has not been achieved.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Control subjects will receive 500mL of normal saline intravenously.
Study: NCT05395052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT536
Description: FT536 is an allogeneic natural killer (NK)-cell immunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT05827822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sober Time ACT
Description: Mental health assessment (regular assessment and reporting feedback), daily clock-in (reporting alcohol use and providing encouragement and reinforcement), mental knowledge base (Tips for the Day based on cognitive behavioral techniques, popular alcohol withdrawal courses, alcohol health education manuals) and self-assistance tools (mindfulness meditation training and emergency help buttons)
Study: NCT06199076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.
Study: NCT05395052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent
Study: NCT06360341

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Discharge Care
Description: Routine Discharge Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Discharge Care
Description: Routine Discharge Care
Study: NCT04857034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06114550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity resistance training
Description: The HIRT protocol comprised five exercises (bench press, barbell back squat, deadlift, seated leg flexion, and reverse arm curl) at 80% of 1RM, and 4-5 sets of 12 repetitions with 1-2 minutes of rest period between sets for approximately 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low intensity resistance training
Description: For LIRT protocol, which performed same training exercises as HIRT. The repetitions in the LIRT protocol were assessed using the following equation: 80% of 1RM lifting load (kg) ×repetitions (HIRT)/40% of 1RM to volition fatigue, with 1-2 minutes of rest period between sets. Therefore, the LIRT protocol completed 4-5 sets of 24 repetitions at 40% of 1RM for a total of 60 minutes.
Study: NCT05395052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohort AA ONLY: To be combined with FT536 at the MTD or MAD

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Monoclonal antibody

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For Cohorts C/CC, the combination product (monoclonal antibody) will be ONE of the following: pembrolizumab, nivolumab, or atezolizumab.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Monoclonal antibody

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Monoclonal antibody

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: For Cohorts BB-FF ONLY: To be combined with FT536 + mAb at the MTD or MAD
Study: NCT06560671

Intervention type: OTHER
Group type: OTHER
Intervention: novel type of health education
Description: animation video based health education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: novel type of health education
Description: animation video based health education
Study: NCT06173050

Intervention type: DEVICE
Group type: OTHER
Intervention: PAP System A (with Amalfi) then PAP System B (with CLA11)
Description: PAP System A (with Amalfi) for 7 days followed by PAP System B (with CLA11) for 7 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP System B (with CLA11) then PAP System A (with Amalfi)
Description: PAP System B (with CLA11) for 7 days followed by PAP System A (with Amalfi) for 7 days
Study: NCT05906251

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SRP-6004
Description: Single IV infusion of SRP-6004
Study: NCT05235568

Intervention type: DEVICE
Group type: OTHER
Intervention: VALVOSFT intervention
Description: Treatment of the calcific aorta valve by non-invasive ultrasound therapy
Study: NCT05183282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tarsus Patch
Description: The Tarsus Patch is a flexible adhesive device that is applied to the closed upper eyelid and conforms to the curvature of the eyelid to help keep the eyelid in a closed position.
Study: NCT06555939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care Model
Description: The interprofessional team will meet weekly to review survey scores, endorsed psychological and physical health needs, as well as other concerns. They will conduct assessments as a group that may include referrals for additional support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management
Description: PRISM targets 4 resilience resources: stress management, goal-setting, cognitive reframing and meaning-making. It is delivered one-on-one by trained coaches in English or Spanish via HIPAA compliant video-conference or in-person. Sessions are delivered every 1-2 weeks based on patient preference. To facilitate practice between sessions, all participants 13 or older have access to the digital PRISM app.
Study: NCT06623227

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsule contains substances that are safe, non-active, and commonly used in pharmaceuticals (microcrystalline cellulose) with an appropriate coloring dye and in the active arms, Vitamin E and C. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E and C
Description: Capsule Vitamin E (Natural Vitamin E, d-alpha tocopherol) 150 IU or 200 IU containing also Vitamin C 100 mg or 200 mg b.id depending on age. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules
Study: NCT06278233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: TDCS involves applying a weak electrical current across the head through electrodes placed on the scalp and modulating the resting membrane potential of neurons in the underlying cortex.
Study: NCT05673460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Nemtabrutinib tablets will be administered orally QD at dosage of 45 mg or 65 mg
Study: NCT06557369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSEES
Description: The treatment consists of combining SMPL and PBM light therapies to exploit the full advantage of their action. The combination will result in an additive or synergetic effect.~* Treatment sessions are scheduled for three weeks after enrolment (Loading-Phase).~* Two visits per week are needed.~* At the first visit of every treatment week, two treatment sessions will follow each other; PBM is applied at least 15' after SMPL (treatment pairs).~* Only PBM will be administered during the second visit of every treatment week.~Patients will receive:~* 1x SMPL treatment at days 0, 7, and 14 (3 in total),~* 1x PBM treatment at days 0, 3, 7, 10, 14, and 17 (6 in total)~Nine treatments will be delivered within three weeks. The study will be concluded with three follow-up visits at 18, 24, and 54 weeks.
Study: NCT05376202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800CW
Description: Patients will receive 75mg Cetuximab followed by 15mg Cetuximab-IRDye800CW two days prior to surgery
Study: NCT04737122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-061
Description: Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-061
Description: Oral dose with approximately 240 mL water in the fasting condition, and food will be forbidden 1 h prior to administration and 2h after dose. QD for continuous 28 days, and 4 weeks as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: For subjects in combination escalation levels, toripalimab will be administered 240mg, IV, every 3 weeks
Study: NCT05673135

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Hypertensive
Description: For control of the blood pressure

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Hypertensive
Description: For control of the blood pressure

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: For assessment of gestational age and fetal weight

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: For assessment of gestational age and fetal weight

Intervention type: RADIATION
Group type: OTHER
Intervention: Doppler ultrasound
Description: Umbilical artery Doppler assessment
Study: NCT06476587

Intervention type: OTHER
Intervention: Posturography
Description: Participants' ability to maintain their balance will be assessed using measurements taken on the Synapsys platform. To standardise their position, they will have to stand on the platform with their feet apart, arms at their sides and look straight ahead. Volunteers will be asked to sit down between each trial. The surface area and length of the centre of pressure will be measured under open-eye balance conditions with and without image reading/exploration and dynamics. During this test, 9 balance assessment situations lasting approximately 1 minute each will be performed.
Study: NCT05673135

Intervention type: RADIATION
Group type: OTHER
Intervention: Doppler ultrasound
Description: Umbilical artery Doppler assessment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: complete blood count
Description: For assessment of platelet count

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: complete blood count
Description: For assessment of platelet count

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Body mass index
Description: for assessment of maternal weight during pregnancy
Study: NCT06623695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: SGG performed the exercise program on a fixed ground surface. SGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: USGG participants completed the exercise program on a bosuball. USGG exercise participants participated in a core exercise program for a total of 25-30 minutes, 2 days a week for 5 weeks.
Study: NCT05673135

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Body mass index
Description: for assessment of maternal weight during pregnancy
Study: NCT04036058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal gloving
Description: The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.